

**PRODUCT INFORMATION**

|   |   |
|---|---|
| <b>Clone ID</b>                         | DM87  |
| <b>Target</b>                           | PSCA  |
| <b>Synonyms</b>                         | PSCA;UNQ206;PRO232  |
| <b>Host Species</b>                     | Rabbit  |
| <b>Description</b>                      | PE-conjugated Anti-PSCA antibody(DM87), Rabbit mAb  |
| <b>Delivery</b>                         | Under Development   |
| <b>Uniprot ID</b>                       | O43653  |
| <b>IgG type</b>                         | Rabbit IgG  |
| <b>Clonality</b>                        | Monoclonal  |
| <b>Reactivity</b>                       | Human   |
| <b>Applications</b>                     | Flow Cyt  |
| <b>Recommended Dilutions</b>            | Flow Cyt 1:100  |
| <b>Purification</b>                     | Purified from cell culture supernatant by affinity chromatography   |
| <b>Formulation &amp; Reconstitution</b> | Liquid□PBS with 0.05% Proclin300, 1% BSA  |
| <b>Storage &amp; Shipping</b>           | Store at 2°C-8°C for 6 months   |
| <b>Background</b>                       | This gene encodes a glycosylphosphatidylinositol-anchored cell membrane glycoprotein. In addition to being highly expressed in the prostate it is also expressed in the bladder; placenta; colon; kidney; and stomach. This gene is up-regulated in a large proportion of prostate cancers and is also detected in cancers of the bladder and pancreas. This gene includes a polymorphism that results in an upstream start codon in some individuals; this polymorphism is thought to be associated with a risk for certain gastric and bladder cancers. Alternative splicing results in multiple transcript variants. |
| <b>Usage</b>                            | Research use only   |
| <b>Conjugate</b>                        | PE-conjugated   |
| <b>DIMA Disclaimer</b>                  | All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.  |

